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Abstract: In the present study, we describe and compare the binding modes of three 
Lycopodium alkaloids (sauroine, 6-hydroxylycopodine and sauroxine; isolated from Huperzia 
saururus) and huperzine A with the enzyme acetylcholinesterase. Refinement and rescoring of the 
docking poses (obtained with different programs) with an all atom force field helped to improve the 
quality of the protein-ligand complexes. Molecular dynamics simulations were performed to 
investigate the complexes and the alkaloid’s binding modes. The combination of the latter two 
methodologies indicated that binding in the active site is favored for the active compounds. On the 
other hand, similar binding energies in both the active and the peripheral sites were obtained for 
sauroine, thus explaining its experimentally determined lack of activity. MM-GBSA predicted the 
order of binding energies in agreement with the experimental IC50 values.  
 
Keywords: Lycopodium alkaloids, sauroxine, acetylcholinesterase inhibitors, docking, molecular 
dynamics. 
 
Highlights:  
 The binding mode of Lycopodium alkaloids with AChE was investigated. 
 Refinement and rescoring of the docking poses improve the results. 
 MM-GBSA analyses from MD simulations predicted the binding energies. 
 Active compounds had a preference for binding at the active site. 
 Sauroine (inactive) presented similar ΔGBinding for the active and peripheral sites. 
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 Introduction 
 
Alzheimer’s disease (AD) is the most common cause of dementia in elderly people. Unfortunately, 
to date an effective cure or even preventive therapy remains elusive.[1] Most of the available 
treatments have only a palliative effect, providing a temporary retention of cognitive and memory 
functions, but without altering the disease’s progression.[2] 
In the 70's and in the 80's the basis of the cholinergic hypothesis began to be understood,[3] 
thereby providing for the first time a rational approach to the treatment of memory loss in AD. 
Improvements in cognitive abilities in AD patients were achieved by blocking or disrupting the 
acetylcholinesterase (AChE) activity with reversible inhibitors. After the pioneering findings of 
Inestrosa et al.,[4, 5] the amyloid hypothesis for the AD’s pathogenesis was proposed, by which the 
accumulation of amyloid β (Aβ) aggregates triggers a cascade of neurotoxic events in the brain 
eventually leading to a widespread neuronal degeneration and hence to dementia. As a consequence, 
new anti-Alzheimer drug candidates focused on this problem, in order to modify the stage of the 
disease.[6]  
 In silico methods were also used to enhance the understanding of AChE and to assist in the 
design of new inhibitors (AChEIs).[7-11] The first computational studies were carried out with the 
Torpedo Californica Acetylcholinesterase (TcAChE), whose first crystal structure appeared in 
1991.[12] This also helped understanding the function[13, 14] and the interaction of the enzyme 
with the inhibitors. The residues responsible for the catalytic activity of AChE, the catalytic triad 
(Ser203, His447, Glu334),[15] are found at the bottom of a 20 Å deep gorge or cavity that 
constitutes the active site (AS), see Figure 1. In this gorge, there are also three other subsites, named 
after the binding of the acetylcholine: the anionic subsite (formed by Trp86, Tyr133, Glu202), the 
oxyanion subsite (Gly121, Gly122 and Ala204) and the acyl-binding subsite (Trp236, Phe295, 
Phe297 and Phe338). At the top of the gorge, there is a couple of aromatic residues, Tyr124 and 
Phe338, which form the so-called “bottleneck” that opens and closes and acts as a gate to the AS. 
Outside the gorge, next to the “entrance”, there is another site called the peripheral anionic site 
(PAS), where the precursors of the A are proposed to deposit before aggregation.[16, 17] 
Moreover, it has been shown that molecules able to interact with both sites of AChE (i.e. a dual-site 
inhibitor) were able to prevent the aggregating activity of AChE toward A as well as the 
hydrolysis of acetylcholine.[18] Therefore, inhibitors with the dual-site binding mode have recently 
been presented as a new therapeutic option.[6]  
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Figure 1. Schematic description of the active site of the AChE and the corresponding subsites.  
 
It is recognized that natural products can play an important role as inhibitors of the AChE, or 
as templates for the development of new synthetic AChEIs.[19] Among these compounds are found 
physostigmine (1),[20-22] Huperzine A (2),[23, 24] and galanthamine (3).[25, 26] Other AChEIs of 
relevance, but obtained by synthesis, are Tacrine (4),[27] donepezil (5)[28, 29] and rivastigmine 
(6),[30] the latter being a semi-synthetic derivative of 1. Last but not least, there is a family of 
compounds originated by a fusion between the tacrine and huperzine A cores, namely the huprine 
family (7),[31, 32] i.e. huprine X (8),[33, 34] which also act as useful AChEIs, but are not yet 
approved by FDA. All these compounds bind to the bottom of the gorge and block the action of the 
catalytic triad.[35-40]  
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Scheme 1. AChE inhibitors  
 
 Alkaloids are among the strongest AChEIs,
 
and hence there is a constant search for new 
alkaloids with inhibitory properties. Over 200 Lycopodium alkaloids have been reported, but only 
some of them have shown to b  good AChEIs.[41] A number of plants have also been used in 
traditional medicine for the treatment of memory and cognitive disorders, such as H. serrata, from 
which some Lycopodium alkaloids with promising AchE inhibitory activity were obtained. With the 
aim of exploiting the properties of these alkaloids, based on Argentinian folk medicine, an 
investigation was conducted on Huperzia saururus (Lam.) Trevis. (Lycopodeaceae). This species is 
commonly known as “cola de quirquincho”, whose aerial parts are consumed as an infusion or a 
decoction because of their claimed folk use as an aphrodisiac[42] or for improving memory.[43] 
Previous studies on H. saururus collected in Pampa de Achala (Córdoba), Argentina, showed the 
presence of eight different alkaloids in a purified alkaloid extract, with sauroine (9), being the 
predominant one (Scheme 2).[21, 44] The purified alkaloid extract of H. saururus was shown to be 
active as an AChEI,[45, 46] although the major alkaloid (9) was not. The IC50 values for the 
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Lycopodine Class of alkaloids were similar to those of other alkaloids from the same class[47] but 
based on the experimental information available, the lycopodine type alkaloids may be less active 
than the lycodine type. 
 
 
Scheme 2. Proposed AChEI extracted from Huperzia saururus  
 
In order to rationalize the relationship between the structure of the alkaloids and their 
activities, we studied the interaction of the alkaloids 9-11 (isolated from H. saururus, Scheme 2) 
with AChE by using the computational methods of docking and molecular dynamics (MD) 
simulations. For a better comprehension, compounds 9 and 10 were grouped together due to their 
structural similarities (both belong to Lycopodine Class (Scheme 2-a)) and compound 11 was 
compared with 2, which was used as a reference, as both are from the Lycodine Class (Scheme 2-
b).[48]  
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Materials and Methods 
 
Experimental Information 
Lycopodium alkaloids. Sauroine (9), 6-hydroxylycopodine (10) and sauroxine (11) were isolated, 
purified and identified as previously reported.[21, 44-46, 49] 
Anticholinesterase activity assay 
Enzyme source. Erythrocyte membranes were used as the enzyme source and were obtained as 
previously informed.[21, 44-46] 
Determination of the inhibitory effect.  The acetyl cholinesterase assay was performed using the 
colorimetric method of Ellman and co-workers,[50] with some modifications incorporated by our 
group. In order to calculate the activity, the following procedure was employed: 750 μL of 
phosphate buffer (50mM, pH 7.2), containing 0.25 mM of 5,5´-dithiobis-2-nitrobenzoic acid (buffer 
+ DTNB), 5 µL enzyme preparation, 25 µL of acetylthiocholine iodide 5 mM, and 100 µL of 
distilled water, were mixed and incubated for 30 minutes. Afterwards, the measurements were taken 
once every 30 seconds over the next 3 minutes, at 25° C. All experiments were repeated three times. 
Different concentrations of sauroine (9), 6-hydroxylycopodine (10) and sauroxine (11), in a range of 
2-700 µM, were required for 50% enzyme inhibition (IC50). The IC50 values were estimated from a 
non-linear fitting of the concentration-response data, using the GraFit 6.0 software. Physostigmine 
salicylate was employed as the reference inhibitor for comparison of the anticholinesterase 
activity.[21, 44-46] 
 
Computational Methods 
Docking Simulations. The programs Autodock 3 (A3),[51] Autodock 4.2 (A4.2)[52] and Autodock 
Vina (AV)[53] were used for the docking simulations with the ff99[54] force field charges for the 
protein residues. The starting coordinates of the protein were those of the X-ray structure 3LII[13] 
and all the water molecules were removed. The coordinates of the missing residues (Pro259, 
Gly260, Gly261, Thr262 and Gly263) were added with the side chain prediction tools included in 
Maestro.[55] The protonation states of the amino acids in the protein were assigned with the H++ 
server,[56, 57] and the ones of the residues in the catalytic gorge (His447, Glu334, Glu202 and 
Asp74) on the basis of previous representative work by McCammon et al.[58] For A3 and A4.2, the 
search that provided the best exploration was found to be the combination of the genetic algorithm 
and a local search refinement (GA-LS). The search space was defined using AutoGrid, and the same 
grid was used for all the simulations with the three programs. It was centered in the gorge, between 
Trp86 and Tyr337, with a size of 82 × 88 × 80 points and a grid spacing of 0.375 Å. The programs 
A3 and A4.2 had the same search parameters: step sizes of 2.0 Å for translation and 50º for rotation. 
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The maximum number of energy evaluations was set to 1 x 10
7
 and the maximum number of 
generations to 5 x 10
5 
on a single population of 50 individuals. For each compound, 500 geometries 
were generated and clustered with an RMSD threshold value of 0.5 Å. In the case of AV an energy 
range of 5 kcal/mol was employed, with a maximum number of 10 geometries and an 
exhaustiveness of 100. 
Non-standard residue parameterization. The construction of each of the substrate units to be 
used in the MD and docking simulations was achieved with the antechamber module, using the 
GAFF force field[54, 59, 60] and employing the restricted ESP (RESP) charges obtained from a 
single point HF/6-31G*[60-62] quantum chemical calculation of the B3LYP/6-31+G* optimized 
structure within the Gaussian 03 package.[63] A list of the energies (zero point corrected (ZP)) and 
xyz coordinates of the optimized geometries of the ligands is included in the supplementary 
material (SM). 
MD Simulations. The same starting geometry (3LII)[13] was used as in the docking studies. For 
running the simulations, the ff99[54] force field was employed and the input files for the 
simulations were built with the xleap package included in ambertools.[64] The whole system was 
neutralized and then solvated with TIP3P[65] water within 8.5 Å around the protein, forming a 
rectangular box with a total number of 56000 atoms.  
MD simulations were run with the NAMD (version 2.8) program[66] at 300 K and applying 
periodic boundary conditions. Non-bonded interactions were calculated using a 13.0 Å neighboring 
group list updated every 10 steps of the dynamics. Van der Waals interactions were truncated at 11 
Å applying a smooth switching function that started at 8 Å. All electrostatic interactions beyond 11 
Å were computed with the particle-mesh Ewald summation[67] and all covalent bonds involving 
hydrogens were constrained using the SHAKE algorithm.[66, 68] The trajectories obtained with 
NAMD were analyzed with VMD[69] and the ambertools programs.[64] 
Before starting the MD production stage, three steps were performed. Firstly, two 5000 
minimization steps, with the first one keeping the protein heavy atoms restrained at their initial 
positions and the second one with the whole system free. Secondly, 75 ps of simulation in an NTV 
ensemble at 300 K were performed, once again with the motion of the protein atoms restrained. 
After these preparation steps, 20 ns of MD within an NPT ensemble at 300 K were completed. The 
simulations of the AChEI complexes were run following the same procedure and the starting 
geometry was obtained from the docking simulations, with the total time of the simulation being 15 
ns.  
The python based scripts implemented in Amber11[70] were used to  calculate the binding 
free energies within the molecular mechanic-Poisson-Boltzmann surface area (MM-PBSA) and the 
molecular mechanic-Generalized Born surface area (MM-GBSA) approximations.[71, 72] For these 
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calculations, only the geometries of the last 5 ns of each MD run were taken into account.  
 
Results and discussion 
 
AChE inhibitory activity 
The IC50 values for 9, 10 and 11 were determined by the Ellman method[50] following the 
procedure introduced in the experimental section. The results can be observed in Table 1. 
 
Docking Simulations  
Before starting the docking simulations, the pKa of compounds 2, 9-11 were evaluated using a 
simple approximation[73] whose standard deviation had been previously estimated to be less than 
0.5 pKa units.[74] In all cases, the calculated pKa values were above 8.3. Therefore, their 
predominant form, under physiological conditions, was expected to be the protonated one. These 
were the only states considered for the alkaloids under study. The stabilities of the neutral and 
protonated stereoisomers of alkaloid 11 with its N-methyl group in either the axial or equatorial 
position were evaluated by DFT calculations. It was found that the neutral and the protonated forms 
were more stable with the N-methyl in the axial position, so the geometry of this stereoisomer was 
employed for the calculations (Scheme 3). 
 
 
Scheme 3. Different conformers of 11 according to the position of the -N-methyl group.  
 
A control search was performed with the complex TcAChE(huprine X) and compared with 
the experimental one (1E66).[33] Different algorithms were tested and the parameters within the 
search were refined, with the best results being obtained with the GA-LS algorithm as described in 
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the material and methods section. The geometries obtained were close to the experimental one 
(RMSD difference of 0.55 Å), thus validating the procedure used. These geometries are presented 
in Figure S1 of Supplementary Material (SM). 
 To determine the preferred site for binding of the alkaloids 2, 9-11 in the human AChE, 
different docking programs were employed. At the first stage, starting from a minimized structure 
of the enzyme (3LII),[13] the search was carried out within a box including the whole protein. The 
most stable poses were located in two regions: the AS and the PAS. Accordingly, a smaller grid box 
was employed in all the docking simulations, taking into account only these two sites in order to 
obtain refined binding energies and docking poses. To simplify the analysis, the differences in 
Gbinding between the AS and the PAS are represented in Figure 2. The light bars (Gbinding < 0), 
show a preference for the AS, while the dark ones (Gbinding > 0) for the PAS. More details are 
included in Table S1 of the SM.  
 
Figure 2. Preference for the binding at the AS and PAS sites obtained with different procedures. The 
histograms represent the difference in binding free energies (GBindingGBinding AS –GBinding PAS). 
Light bars show a preference for the AS while dark ones show a predilection for the PAS.  
 
Although the graphics revealed different tendencies, in most cases the Gbinding were below 
the estimated error of the Autodock’s scoring functions ( 2.5 kcal/mol).[52, 53] This has been 
ascribed to the different scoring functions used, issue that has been previously addressed.[9, 75, 76] 
Despite the differences in absolute binding energies, it is important to point out that the top poses 
obtained for each site were similar for the three docking procedures employed. The results were 
normalized by rescoring the binding energy of each of the final geometries. In order to carry this 
out, all the complexes obtained were neutralized with counter ions, solvated and minimized[77] by 
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using the parameters of the ff99 and GAFF force fields. Afterwards, the binding energies were 
calculated using the MM-PBSA and MM-GBSA approaches,[71, 72] as proposed by Kunh et 
al.[78] After this procedure, the most favored poses corresponded to the proposed inhibitors at the 
AS site, the exception being compound 9 which had comparable binding energies for the AS and 
PAS sites, but with a slight discrepancy between MM-GBSA and MM-PBSA.  
The geometries of the proposed inhibitors for both sites, obtained after the minimization of 
the docking geometries, are represented in the SM together with the interactions with the protein 
residues, Figures S2-5.[79, 80] When comparing the poses at the AS, it could be seen that 9 and 10 
were almost located in the same place, independently of the position of the substituents. On the 
other hand, 11 and 2, despite having similar molecular structures and sizes, adopted different 
geometries, while 11 had the C and D rings over Trp86 with the carbonyl pointing at the entrance of 
the gorge, compound 2 had the A and B rings over Trp86, with the third ring being perpendicular 
and pointing at the entrance of the gorge. This geometry was similar to the one in the X-ray 
structure of the TcAChE(2) complex.[35] An interesting question arose when inspecting the 
different arrangements adopted by 2 and 11 at the AS. When 11 was put in a conformation similar to 
that of 2, a high steric repulsion arose due to the proximity of the CH2 groups of C9 and C10 to the 
indole and phenol rings of Trp86 and Tyr337, respectively. This new geometry will be defined as 
11b (geometry of 11 aligned with 2) and is represented in Figure S6 of SM. However, when this 
conformation was forced, and the complex was minimized, a MM-GBSA binding energy of -39.5 
kcal/mol (similar to the -38.1 kcal/mol estimated by the same method for the other conformation, 
see Table S1) was obtained. Based on these results, the new conformation of 11 (11b) was also 
explored by MD simulation and compared with the one obtained by the docking procedure (11a). 
On the other hand, when 2 was forced to adopt the geometry of 11a, a steric hindrance between the 
allylic methyl at C10 of 2 and the hydroxyl group of Tyr133 arose, and this new complex afforded a 
higher binding energy than the one obtained by the original docking conformation (-33.4 vs -40.4 
kcal/mol, respectively, after MM-GBSA refinement). These two pairs of geometries are represented 
in Figure S7 of SM. 
There was no correlation between the binding energies obtained from the docking 
calculations and the experimental IC50 values (see Table 1 of the SM). Although refinement and 
recalculation with MM-PBSA or MM-GBSA improved the results, some discrepancies remained. In 
an attempt to determine a better correlation with the experimental results, MD studies were carried 
out for the complexes of the human AChE with 2, 9-11 both inside and outside the gorge. 
 
Molecular Dynamic Simulations  
A simulation of the protein without any ligand was carried out, with the RMSD profiles of the 
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simulations showing, as expected, that the presence of the ligands at the AS or at the PAS did not 
produce any changes in the global RMSD profiles (Figure 3-a; Figures S8-S10 of SM). As reported 
in other simulations on the same protein, the RMSD of the backbone and the global one were 
around 2 and 2.6 Å, respectively.[81]  
 
 
Figure 3. a) Evolution of the RMSD of the backbone of the protein for the MD runs of AChE and 
AChE with compounds 9-11 and 2 at the AS. b) Evolution of the RMSD of the ligands at the AS, 
without considering the hydrogen atoms. c) Evolution of the RMSD of the ligands at the PAS, 
without considering the hydrogen atoms. The same color was employed in all the graphics for 
representing the properties of each MD run. AChE (), AChE-9 (), AChE-10 (), AChE-11a (), 
AChE-11b ()  and AChE-2 ().  
 
An analysis of the RMSD of the ligands in both sites was performed (Figures 3b-c), which 
revealed different profiles inside and outside the gorge related to the topology of the sites. As 
expected, bigger variations of the RMSD were observed at the PAS, which is a wide place to host 
the inhibitor.   
 The binding energies of the MD-complexes were obtained by applying the post-processing 
methods MM-GBSA and MM-PBSA.[71, 72] Recently, it was proposed that even though the 
performance of these methods may be system dependent, they could still give good results to 
compare relative binding energies of similar systems.[82] The Poisson Boltzmann model (PB) is 
theoretically more rigorous than the Generalized Born model (GB), and hence MM-PBSA is often 
considered to be naturally superior to MM-GBSA for predicting the free energies of binding. 
However, in our system, MM-GBSA showed less deviation, and hence for simplicity only the 
results with this model are presented in Table 1. For informative reasons, the values obtained with 
MM-PBSA are included in the SM, Table S2.  
MM-GBSA succeeded in the prediction of 2 and 9 as the best and worst inhibitors, 
respectively. Moreover, the binding energies in the two explored sites were similar only in the case 
of 9. If the binding in the PAS were preferred over AS, then the compound should be inactive or 
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only present a low inhibitory activity, and this indeed may have been the case. For all the other 
compounds, the binding at the AS was preferred over the PAS.  In the case of compound 11, from 
the two geometries explored at the AS, the huperzine like geometry (11b, Table 1) was more 
favorable for binding. For 10 and 11a there were small differences in the binding energies, but the 
binding of 11, in its b pose, was more favorable even when the entropy was included. It should be 
noted that after the inclusion of the entropic term, some of the GBinding were positive, probably due 
to an overestimation of the entropic term. For its evaluation the quasi-harmonic entropy 
approximation was employed instead of the time consuming normal mode analysis of the harmonic 
frequencies.  However, the order of the binding energies was the same as that expected on the basis 
of the experimental values of IC50.   
 
Table 1. MM-GBSA Calculated Binding Energies for the AChE complexes. 
Inhibitor 
EBinding
 
(kcal/mol) GBinding
 
(kcal/mol) IC50 (M)
 a
 
AS PAS AS PAS  
9  -27.3  3.3 -27.8  3.2 11.3 3.3 10.2  3.2 Inactive 
10 -34.2  2.8 -25.8  2.4 2.6  2.8 12.1  2.4 296.8 
11 
a) -38.2  2.5 
b) -41.4  2.7 
-25.5  2.0 
3.3  2.5 
0.5  2.7 
16.3  2.0 32.3 
2 -47.7  2.8 -30.2  2.3 -8.1  2.8 10.8  2.3 0.082[83] 
a
 Experimental values of IC50 are informed in M. These values were determined 
according to the Ellman method,[50] with some modifications, as described in 
the experimental section. 
 
 
With the aim of identifying the residues that helped to stabilize the inhibitor of the obtained 
complexes, a decomposition of the binding energy per residue was performed.[84] A detailed 
description of this decomposition for the AS is included in Figure 4, and the main interactions with 
the protein residues of the AS are shown in Figures 5 and Figures S11-S15 of the SM. This revealed 
that at the AS site the van der Waals interactions with the indole ring of Trp86 were the most 
stabilizing ones for almost all the studied compounds, see Figure 4.  
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Figure 4. Per-residue contributions to the binding energy calculated with MM-GBSA from 
the MD simulations of 9-11, 2 at the AS site. AChE-9 (), AChE-10 (), AChE-11a (), AChE-11b 
() and AChE-2 (). 
 
In the case of 9, the B and D rings and the protonated nitrogen (R3NH)
+
 at position 1 are 
coplanar with the Trp86 of the anionic subsite (Figure 5a). The hydroxyl group at C7 formed a 
hydrogen bond with the carboxylate group of Glu202 during 75% of the MD run, with the other 
observed stabilizations being du  to van der Waals interactions with the aromatic residues Tyr337 
and Tyr449 and those between the oxygen of Ser125 with the CH2 groups of rings A and B. 
As observed for the C7 hydroxyl group of 9, the OH at C6 of compound 10 also formed a 
hydrogen bond with the carboxylate of Glu202 throughout the MD run (Figure 5b). In agreement 
with the average O-H - O=C distance (1.60 Å), this bond could be considered to be stronger than 
the one formed by compound 9, reflected in a bigger stabilizing effect. Besides, the oxygen of this 
hydroxyl group acted as hydrogen acceptor of the N-H amide group of Gly121, with the 
interactions with Trp86 and Ser125 being less important. Finally, a similar profile to that of 9 was 
observed for the van der Waals interactions with Tyr337 and Tyr449.  
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Figure 5. 3-D plot of the final geometries obtained after 15 ns of MD simulation. For the 
complexes: a) AChE-9, b) AChE-10, c) AChE-11a d) AChE-2, e) AChE-11b (similar to 2). f) 
Comparison of the geometries: 11a (represented with balls and sticks) and 11b (represented with 
bold sticks). The hydrogen bonds are represented by black dotted lines. 
 
Several differences may be pointed out by comparing the geometries 11a-b (Figures 5c,e-f ). 
First, for 11a the hydrogen bond of -NH+ with Ser125 was the most stabilizing contribution, with 
the NH also forming a hydrogen bond with the hydroxyl of Ser203. However, the positive 
character of -NH+ made its interaction markedly stronger. On the other hand, for 11b -NH+ did 
not form any hydrogen bond, and the van der Waals interactions with Trp86 were the most 
a) b) 
c) d) 
e) f) 
Page 16 of 23
Ac
ce
pte
d M
an
us
cri
pt
important. Another important difference was the contribution of Glu202. While for 11a, no 
hydrogen bond with Glu202 was formed, thus affording a destabilizing contribution to the binding 
energy. In the case of 11b, the hydrogen bond with this residue helped to stabilize the complex even 
though the interaction did not persist throughout the whole simulation.  
Finally, 2 presented van der Waals interactions with Trp86 and Tyr337, in addition to the 
hydrogen bond between NH and the carboxylate of Glu202, and also a new stabilizing 
component due to the salt bridge between NH3
+
and the carboxylate group of Asp74 (Figure 5d). 
As mentioned above in the simulations of the AChEI complexes with the ligand at the PAS, 
the inhibitors moved from their initial positions. This fact could be explained due to the topology of 
the PAS and its exposure to the solvent. The most important interactions at the PAS were those 
between 9, 10 and 11 with Trp286.[85] A per residue decomposition of the interactions of the 
studied compounds, at the PAS, with the protein is presented in Figure S16 of SM. 
The order of the binding energies for all the studied compounds could be clearly established 
using the MM-GBSA approach, with 2 being the best inhibitor and 9 the worst. This could also 
have been related to the order of the IC50 values as the right order was obtained with the MM-
GBSA approximation. Nevertheless, it is important to remark that this is only one aspect of the 
binding, and that the kinetic of the entrance as well as that of the exit of the inhibitor from the gorge 
should also be evaluated as these two processes might play very important roles in the global 
process of inhibition. Although this is beyond the scope of the present article, it should be born in 
mind for future studies.  
 
Concluding remarks 
 
The Lycopodium alkaloids 10 and 11 have been shown to be inhibitors of the AChE activity, 
whereas a very similar compound 9 had no inhibitory activity. The binding modes of these 
inhibitors in AChE were explored with docking calculations, and similar geometries but different 
binding energies were obtained with the employed programs. Using this approach, a better scoring 
was obtained to improve the quality of the estimation of the binding energy by incorporating an all 
atom force field and the MM-GBSA (MM-PBSA) methods for its calculation. This refinement 
permitted a better discrimination between the active and inactive compounds, with the binding 
preferences for the AS and the PAS sites. 
Molecular dynamics simulations were carried out for the AChE complexes with the 
alkaloids 9-11 and 2, and the binding modes at both sites of the protein were studied. MM-GBSA 
succeeded in ordering the alkaloids according to their inhibitory activities or binding energies. The 
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lack of activity in 9 may be ascribed to the similar binding energies for the AS and the PAS, and the 
compounds with higher activities presented higher affinities for the AS than the PAS.   
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